Yes. Curing hepatitis C lowers the chance of developing liver cancer because it removes the virus that can keep damaging the liver. The risk does not fall to zero, especially when the liver already has cirrhosis, or advanced scarring. People who have had cirrhosis before treatment usually still need regular liver-cancer checks after cure. Treating hepatitis C early, before lasting scarring develops, offers an important long-term benefit.
How does curing hepatitis C reduce liver cancer risk?
Hepatitis C is a viral infection that can cause long-term liver inflammation, scarring, and cirrhosis. Cirrhosis is advanced scarring that changes the liver's structure and increases the chance of developing hepatocellular carcinoma, the most common type of primary liver cancer. Clearing the virus removes an important cause of ongoing liver injury and reduces the likelihood of future complications.
According to the Centers for Disease Control and Prevention (CDC), hepatitis C treatment can prevent serious complications, including liver cancer. Modern antiviral medicines, called direct-acting antivirals, cure more than 95% of people who receive treatment. These medicines work against the virus rather than directly treating cancer.
What does it mean to be cured of hepatitis C?
A successful treatment course is generally considered a cure when a blood test shows that hepatitis C virus RNA is undetectable at least 12 weeks after treatment ends. This outcome is called a sustained virologic response (SVR). It means the virus is no longer detectable in the blood, and the infection is considered cured.
The University of Washington's Hepatitis C Online program explains that an undetectable hepatitis C virus RNA result 12 or more weeks after treatment is the standard measure of cure. This result is important because successful viral clearance is associated with a lower risk of liver cancer. However, it does not establish that all previous liver damage has disappeared.
How much does a hepatitis C cure lower liver cancer risk?
The reduction can be substantial, although the benefit depends partly on the condition of the liver before treatment. The National Cancer Institute (NCI) summarizes evidence from a large observational study in which people who achieved a sustained virologic response had approximately 75% lower relative risk of hepatocellular carcinoma than people who did not achieve that response. This is a relative reduction, not a 75-percentage-point reduction in an individual's absolute risk.
The finding supports treating hepatitis C successfully, but it should not be interpreted as a guarantee against cancer. Research findings can vary, and a person's remaining risk depends on factors such as existing liver scarring and other liver diseases. People who clear the virus without having developed cirrhosis generally have a lower ongoing risk than those who had cirrhosis before treatment.
Why can liver cancer still develop after hepatitis C is cured?
The main reason is that removing the virus does not necessarily reverse all the damage caused by a long-standing infection. Liver tissue can develop extensive scar tissue over many years. When cirrhosis is already present, the risk of liver cancer remains increased even after hepatitis C has been successfully treated.
Some people experience improvement in liver health after a cure, and liver scarring may decrease over time. However, the amount of improvement varies. A previous diagnosis of cirrhosis remains important when planning follow-up care, even if liver blood tests improve or later assessments suggest that scarring has decreased.
Other conditions can also contribute to liver cancer risk. According to the National Cancer Institute's overview of liver cancer risk factors, heavy alcohol use, obesity, type 2 diabetes, and certain other liver conditions are associated with increased risk. Clearing hepatitis C does not remove these separate risks.
Who needs liver cancer screening after hepatitis C treatment?
Follow-up depends largely on how much liver damage was present before the virus was cleared. Healthcare professionals use previous test results, medical history, and appropriate assessments of liver scarring to decide whether ongoing cancer surveillance is needed.
People with cirrhosis
People who had cirrhosis before achieving a cure generally need continued liver cancer surveillance. The American Association for the Study of Liver Diseases (AASLD) recommends surveillance for adults with cirrhosis, including those whose hepatitis C has been cured. According to guidance summarized by the University of Washington's Hepatitis C Online program, this typically involves a liver ultrasound and a blood test for alpha-fetoprotein (AFP) about every six months.
Ultrasound creates images of the liver, while AFP is a blood marker that may be elevated in some people with liver cancer. Neither test is perfect on its own. If surveillance results are concerning, a healthcare professional may recommend additional imaging, such as a CT scan or MRI.
People with advanced liver scarring but no cirrhosis
Recommendations are less uniform for people who have advanced fibrosis, meaning substantial liver scarring that has not progressed to cirrhosis. The AASLD does not recommend routine liver cancer surveillance solely for advanced fibrosis without cirrhosis after hepatitis C cure. Some other clinical guidelines recommend surveillance for selected people in this group. The appropriate plan depends on the degree of scarring, other risk factors, and the clinical guidance being followed.
People without cirrhosis
For most people who achieve a hepatitis C cure before cirrhosis develops, routine liver cancer surveillance is not generally recommended solely because they previously had hepatitis C. They should still receive appropriate medical care for other liver conditions or risk factors when present. If the extent of previous liver damage is unclear, reviewing earlier records or reassessing liver fibrosis can help clarify whether surveillance is needed.
What can help protect the liver after a cure?
Successful hepatitis C treatment is an important step toward protecting long-term liver health. Other measures may also help reduce preventable liver damage:
- Avoid heavy alcohol use. Discuss alcohol avoidance with a healthcare professional, particularly if cirrhosis or another chronic liver condition is present.
- Manage other health conditions. Appropriate care for type 2 diabetes, excess body weight, and metabolic liver disease can help address other contributors to liver damage.
- Keep recommended follow-up appointments. Attend liver assessments and cancer surveillance when indicated, even if you feel well after treatment.
- Understand the possibility of reinfection. A cure does not provide immunity against hepatitis C. People who experience new exposure risks may need repeat testing and should discuss prevention with their healthcare professional.
When should you discuss your follow-up plan with a healthcare professional?
Anyone who has completed hepatitis C treatment should know whether the virus was successfully cleared and whether significant liver scarring was present before treatment. If cirrhosis was diagnosed, it is especially important to establish a continuing surveillance schedule rather than assuming that a cure eliminates the need for cancer checks.
Ask your healthcare professional to clarify your previous fibrosis assessment, whether liver cancer surveillance is appropriate, and when your next ultrasound or other recommended test should take place. If you have not had your liver damage assessed, or you are unsure whether earlier findings showed cirrhosis, a review of your records can help guide follow-up.
The key message: Curing hepatitis C substantially lowers liver cancer risk, but the remaining risk depends on the liver's condition and other health factors. Early treatment and appropriate follow-up work together to support better long-term outcomes.